After strong rallies in March and April, the large-cap pharma sector is in a consolidation mode. There is a case of return of investor’s interest in this segment particularly for companies with diversified business exposure due to relative stability in earnings.
Due to this, companies with good earnings set, balance sheet, and relatively better clarity on growth visibility would garner our interest. Dr Reddy's Laboratories perfectly fits into this context.
Watch the accompanying video to know what makes us positive on the stock and why we believe this could be an opportunity for investors with a high-risk appetite.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
